Search

Your search keyword '"Stilgenbauer, Stephan"' showing total 2,887 results
Start Over Author "Stilgenbauer, Stephan"
2,887 results on '"Stilgenbauer, Stephan"'

201. Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Author

Tausch, Eugen, primary, Schneider, Christof, additional, Furstenau, Moritz, additional, Robrecht, Sandra, additional, Yosifov, Deyan Yordanov, additional, Mertens, Daniel, additional, Gregor, Michael, additional, Thornton, Patrick, additional, Staber, Philipp B., additional, Tadmor, Tamar, additional, Levin, Mark-David, additional, da Cunha-Bang, Caspar, additional, Poulsen, Christian Bjørn, additional, Illmer, Thomas, additional, Schöttker, Björn, additional, Janssens, Ann, additional, Christiansen, Ilse, additional, Noesslinger, Thomas, additional, Baumann, Michael, additional, Wendtner, Clemens-Martin, additional, Eldering, Eric, additional, Kreuzer, Karl-Anton, additional, Ritgen, Matthias, additional, Fink, Anna-Maria, additional, Fischer, Kirsten, additional, Kater, Arnon P., additional, Niemann, Carsten Utoft, additional, Hallek, Michael, additional, Eichhorst, Barbara, additional, and Stilgenbauer, Stephan, additional

Published
2022
Full Text
View/download PDF

202. Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study

Author

Brummendorf, Tim H., primary, Medd, Patrick, additional, Koch, Raphael, additional, Stilgenbauer, Stephan, additional, Sharma, Shringi, additional, He, Yun, additional, Meyer, Stefanie, additional, Wey, Margaret C., additional, Saeh, Jamal, additional, Olsson, Richard F., additional, and Kater, Arnon P., additional

Published
2022
Full Text
View/download PDF

203. NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted

Author

Ehrmann, Alena Sophie, primary, Quijada Álamo, Miguel, additional, Close, Viola, additional, Guo, Min, additional, Pérez Carretero, Claudia, additional, Corchete, Luis A, additional, Tausch, Eugen, additional, Schneider, Christof, additional, Döhner, Hartmut, additional, Stilgenbauer, Stephan, additional, Oswald, Franz, additional, Hernández-Rivas, Jesus Maria, additional, and Mertens, Daniel, additional

Published
2022
Full Text
View/download PDF

204. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Author

Hess, Georg, primary, Dreyling, Martin, additional, Oberic, Lucie, additional, Gine, Eva, additional, Zinzani, Pier Luigi, additional, Linton, Kim M., additional, Vilmar, Adam, additional, Jerkeman, Mats, additional, Chen, Jenny MH, additional, Ohler, Anke, additional, Stilgenbauer, Stephan, additional, Thieblemont, Catherine, additional, Lambert, Jonathan, additional, Zilioli, Vittorio Ruggero, additional, Sancho, Juan-Manuel, additional, Jimenez-Ubieto, Ana, additional, Fischer, Luca, additional, Eyre, Toby A., additional, Keeping, Sam, additional, Park, Julie E, additional, Wu, James J, additional, Siddiqi, Rubina, additional, Reitan, John, additional, Castaigne, Gab, additional, and Salles, Gilles, additional

Published
2022
Full Text
View/download PDF

205. Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Author

Parry, Erin Michelle, primary, Guieze, Romain, additional, Leshchiner, Ignaty, additional, Johnson, Connor, additional, Tausch, Eugen, additional, Parikh, Sameer A., additional, Lemvigh, Camilla K, additional, Broséus, Julien, additional, Hergalant, Sébastien, additional, Messer, Connor, additional, Utro, Filippo, additional, Levovitz, Chaya, additional, Rhrissorrakrai, Kahn, additional, Li, Liang, additional, Li, Shuqiang, additional, Fell, Geoffrey G, additional, Redd, Robert A., additional, Lin, Ziao, additional, Knisbacher, Binyamin A., additional, Schneider, Christof, additional, Fernandes, Stacey M., additional, Hess, Julian M., additional, Rassenti, Laura Z., additional, Kipps, Thomas J., additional, Jain, Nitin, additional, Wierda, William G., additional, Cymbalista, Florence, additional, Feugier, Pierre, additional, Kay, Neil E., additional, Livak, Kenneth J, additional, Danysh, Brian P, additional, Stewart, Chip, additional, Neuberg, Donna S., additional, Davids, Matthew S., additional, Brown, Jennifer R., additional, Parida, Laxmi, additional, Stilgenbauer, Stephan, additional, Getz, Gad, additional, and Wu, Catherine J., additional

Published
2022
Full Text
View/download PDF

206. Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

Author

Huber, Henriette, primary, Tausch, Eugen, additional, Schneider, Christof, additional, Edenhofer, Simone, additional, Von Tresckow, Julia, additional, Robrecht, Sandra, additional, Giza, Adam, additional, Zhang, Can, additional, Furstenau, Moritz, additional, Dreger, Peter, additional, Ritgen, Matthias, additional, Illmer, Thomas, additional, Illert, Anna Lena, additional, Dürig, Jan, additional, Böttcher, Sebastian, additional, Niemann, Carsten Utoft, additional, Kneba, Michael, additional, Fink, Anna-Maria, additional, Fischer, Kirsten, additional, Döhner, Hartmut, additional, Hallek, Michael, additional, Eichhorst, Barbara, additional, and Stilgenbauer, Stephan, additional

Published
2022
Full Text
View/download PDF

207. Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR ‐2 retrospective chart review study

Author

Hess, Georg, primary, Dreyling, Martin, additional, Oberic, Lucie, additional, Gine, Eva, additional, Zinzani, Pier Luigi, additional, Linton, Kim, additional, Vilmar, Adam, additional, Jerkeman, Mats, additional, Chen, Jenny M. H., additional, Ohler, Anke, additional, Stilgenbauer, Stephan, additional, Thieblemont, Catherine, additional, Lambert, Jonathan, additional, Zilioli, Vittorio Ruggero, additional, Sancho, Juan‐Manuel, additional, Jiménez‐Ubieto, Ana, additional, Fischer, Luca, additional, Eyre, Toby A., additional, Keeping, Sam, additional, Park, Julie E., additional, Wu, James J., additional, Siddiqi, Rubina, additional, Reitan, John, additional, Wade, Sally, additional, and Salles, Gilles, additional

Published
2022
Full Text
View/download PDF

208. Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic

Author

Arndt, Volker, primary, Doege, Daniela, additional, Fröhling, Stefan, additional, Albers, Peter, additional, Algül, Hana, additional, Bargou, Ralf, additional, Bokemeyer, Carsten, additional, Bornhäuser, Martin, additional, Brandts, Christian H., additional, Brossart, Peter, additional, Brucker, Sara Yvonne, additional, Brümmendorf, Tim H., additional, Döhner, Hartmut, additional, Gattermann, Norbert, additional, Hallek, Michael, additional, Heinemann, Volker, additional, Keilholz, Ulrich, additional, Kindler, Thomas, additional, von Levetzow, Cornelia, additional, Lordick, Florian, additional, Neumann, Ulf Peter, additional, Peters, Christoph, additional, Schadendorf, Dirk, additional, Stilgenbauer, Stephan, additional, Zander, Thomas, additional, Zips, Daniel, additional, Braun, Delia, additional, Seufferlein, Thomas, additional, Nettekoven, Gerd, additional, and Baumann, Michael, additional

Published
2022
Full Text
View/download PDF

209. Poster: CLL-246 Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 5-Year Results of the Randomized CLL14 Study

Author

Al-Sawaf, Othman, primary, Zhang, Can, additional, Robrecht, Sandra, additional, Kotak, Alex, additional, Chang, Naomi, additional, Fink, Anna, additional, Tausch, Eugen, additional, Schneider, Christof, additional, Ritgen, Matthias, additional, Kreuzer, Karl, additional, Chyla, Brenda, additional, Eichhorst, Barbara, additional, Jiang, Yanwen, additional, Stilgenbauer, Stephan, additional, Hallek, Michael, additional, and Fischer, Kirsten, additional

Published
2022
Full Text
View/download PDF

211. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Author

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M. N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjørn, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C, Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

212. MINCR is a MYC-induced lncRNA able to modulate MYC’s transcriptional network in Burkitt lymphoma cells

Author

ICGC MMML-Seq Consortium, Doose, Gero, Haake, Andrea, Bernhart, Stephan H., López, Cristina, Duggimpudi, Sujitha, Wojciech, Franziska, Bergmann, Anke K., Borkhardt, Arndt, Burkhardt, Birgit, Claviez, Alexander, Dimitrova, Lora, Haas, Siegfried, Hoell, Jessica I., Hummel, Michael, Karsch, Dennis, Klapper, Wolfram, Kleo, Karsten, Kretzmer, Helene, Kreuz, Markus, Küppers, Ralf, Lawerenz, Chris, Lenze, Dido, Loeffler, Markus, Mantovani-Löffler, Luisa, Möller, Peter, Ott, German, Richter, Julia, Rohde, Marius, Rosenstiel, Philip, Rosenwald, Andreas, Schilhabel, Markus, Schneider, Markus, Scholz, Ingrid, Stilgenbauer, Stephan, Stunnenberg, Hendrik G., Szczepanowski, Monika, Trümper, Lorenz, Weniger, Marc A., Hoffmann, Steve, Siebert, Reiner, and Iaccarino, Ingram

Published
2015

214. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

Author

Stachelscheid, Johanna, primary, Jiang, Qu, additional, Aszyk, Christoph Markus, additional, Warner, Kathrin, additional, Bley, Nadine, additional, Müller, Tony A., additional, Vydzhak, Olga, additional, Symeonidis, Konstantinos, additional, Crispatzu, Giuliano, additional, Mayer, Petra, additional, Blakemore, Stuart James, additional, Goehring, Gudrun, additional, Newrzela, Sebastian, additional, Hippler, Stephanie, additional, Robrecht, Sandra, additional, Kreuzer, Karl-Anton, additional, Pallasch, Christian P, additional, Krüger, Marcus, additional, Lechner, Axel, additional, Fischer, Kirsten, additional, Stilgenbauer, Stephan, additional, Beutner, Dirk, additional, Hallek, Michael, additional, Auguin, Daniel, additional, Hüttelmaier, Stefan, additional, Bloehdorn, Johannes, additional, Vasyutina, Elena, additional, and Herling, Marco, additional

Published
2022
Full Text
View/download PDF

215. Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older

Author

Simon, Florian, primary, Giza, Adam, additional, Robrecht, Sandra, additional, Fink, Anna-Maria, additional, Cramer, Paula, additional, von Tresckow, Julia, additional, Fürstenau, Moritz, additional, Goede, Valentin, additional, Tausch, Eugen, additional, Schneider, Christof, additional, Stilgenbauer, Stephan, additional, Wendtner, Clemens-Martin, additional, Eichhorst, Barbara, additional, Fischer, Kirsten, additional, Hallek, Michael, additional, and Al-Sawaf, Othman, additional

Published
2022
Full Text
View/download PDF

216. Exploration of whole genome and transcriptome sequencing data lacks evidence for oncogenic viral elements to drive the pathogenesis of T-cell prolymphocytic leukemia

Author

Patil, Paurnima, primary, Toprak, Umut H., additional, Seufert, Julian, additional, Braun, Till, additional, Bernhart, Stephan H., additional, Wiehle, Laura, additional, Müller, Annika, additional, Schlesner, Matthias, additional, Herling, Marco, additional, Lichter, Peter, additional, Stilgenbauer, Stephan, additional, Siebert, Reiner, additional, and Zapatka, Marc, additional

Published
2022
Full Text
View/download PDF

217. Abstract A13: Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

Author

Parry, Erin M, primary, Leshchiner, Ignaty, additional, Guieze, Romain, additional, Johnson, Connor, additional, Tausch, Eugen, additional, Parikh, Sameer A, additional, Lemvigh, Camilla K, additional, Messer, Conor, additional, Utro, Filippo, additional, Levovitz, Chaya, additional, Rhrissorrakrai, Kahn, additional, Davids, Matthew S, additional, Broseus, Julien, additional, Li, Shuqiang, additional, Lin, Ziao, additional, Knisbacher, Binyamin A, additional, Schneider, Christof, additional, Rassenti, Laura Z, additional, Kipps, Thomas J, additional, Jain, Nitin, additional, Wierda, William, additional, Cymbalista, Florence, additional, Kay, Neil E, additional, Livak, Kenneth J, additional, Danysh, Brian P, additional, Stewart, Chip, additional, Neuberg, Donna, additional, Brown, Jennifer R, additional, Paridi, Laxmi, additional, Stilgenbauer, Stephan, additional, Getz, Gaddy, additional, and Wu, Catherine, additional

Published
2022
Full Text
View/download PDF

219. CLL-465 Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)

Author

Goergen, Ellinor, Tresckow, Julia v., Giza, Adam, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Al-Sawaf, Othman, Moritzürstenau, Moritz, Simon, Florian, Kutsch, Nadine, Nieper, Pascal, Tausch, Eugen, Ritgen, Matthias, Sebastianöttcher, Sebastian, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Langerbeins, Petra, Eichhorst, Barbara, Hallek, Michael, and Cramer, Paula

Published
2024
Full Text
View/download PDF

220. Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)

Author

Goergen, Ellinor, Tresckow, Julia v., Giza, Adam, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Al-Sawaf, Othman, Fürstenau, Moritz, Simon, Florian, Kutsch, Nadine, Nieper, Pascal, Tausch, Eugen, Ritgen, Matthias, Böttcher, Sebastian, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Langerbeins, Petra, Eichhorst, Barbara, Hallek, Michael, and Cramer, Paula

Published
2024
Full Text
View/download PDF

221. Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study

Author

Sutton, Lesley-Ann, Ljungström, Viktor, Enjuanes, Anna, Cortese, Diego, Skaftason, Aron, Tausch, Eugen, Kozubik, Katerina Stano, Nadeu, Ferran, Armand, Marine, Malcikova, Jikta, Djureinovic, Tatjana, Forster, Jade, Davis, Zadie, Oscier, David, Rossi, Davide, Ghia, Paolo, Strefford, Jonathan C., Pospisilova, Sarka, Stilgenbauer, Stephan, Davi, Frederic, Campo, Elias, Stamatopoulos, Kostas, Rosenquist, Richard, Karolinska Institutet [Stockholm], Uppsala University, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), University of Ulm (UUlm), Central European Institute of Technology [Brno] (CEITEC MU), Brno University of Technology [Brno] (BUT), Service d'Hématologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), University of Southampton, Oncology Institute of Southern Switzerland (IOSI), Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), IRCCS Ospedale San Raffaele [Milan, Italy], Karolinska University Hospital [Stockholm], Sutton, Lesley-Ann, Ljungström, Viktor, Enjuanes, Anna, Cortese, Diego, Skaftason, Aron, Tausch, Eugen, Stano Kozubik, Katerina, Nadeu, Ferran, Armand, Marine, Malcikova, Jikta, Pandzic, Tatjana, Forster, Jade, Davis, Zadie, Oscier, David, Rossi, Davide, Ghia, Paolo, Strefford, Jonathan C, Pospisilova, Sarka, Stilgenbauer, Stephan, Davi, Frederic, Campo, Elia, Stamatopoulos, Kosta, and Rosenquist, Richard

Subjects
Cytogenetics and Molecular Genetics, [SDV]Life Sciences [q-bio], Mutation, Next-generation sequencing, High-Throughput Nucleotide Sequencing, Humans, Chronic Lymphocytic Leukemia, Hematology, Hematologi, Genomics, Precision Medicine, Leukemia, Lymphocytic, Chronic, B-Cell, Article
Abstract

International audience; Next-generation sequencing (NGS) has transitioned from research to clinical routine, yet the comparability of different technologies for mutation profiling remains an open question. We performed a European multicenter (n=6) evaluation of three amplicon-based NGS assays targeting 11 genes recurrently mutated in chronic lymphocytic leukemia. Each assay was assessed by two centers using 48 pre-characterized chronic lymphocytic leukemia samples; libraries were sequenced on the Illumina MiSeq instrument and bioinformatics analyses were centralized. Across all centers the median percentage of target reads ≥100x ranged from 94.2- 99.8%. In order to rule out assay-specific technical variability, we first assessed variant calling at the individual assay level i.e., pairwise analysis of variants detected amongst partner centers. After filtering for variants present in the paired normal sample and removal of PCR/sequencing artefacts, the panels achieved 96.2% (Multiplicom), 97.7% (TruSeq) and 90% (HaloPlex) concordance at a variant allele frequency (VAF) >0.5%. Reproducibility was assessed by looking at the inter-laboratory variation in detecting mutations and 107 of 115 (93% concordance) mutations were detected by all six centers, while the remaining eight variants (7%) were undetected by a single center. Notably, 6 of 8 of these variants concerned minor subclonal mutations (VAF 5%, after rigorous validation, the use of unique molecular identifiers may be necessary to reach a higher sensitivity and ensure consistent and accurate detection of low-frequency variants.

Published
2020

223. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib

Author

Wolf, Christine, Garding, Angela, Filarsky, Katharina, Bahlo, Jasmin, Robrecht, Sandra, Becker, Natalia, Zucknick, Manuela, Rouhi, Arefeh, Weigel, Anja, Claus, Rainer, Weichenhan, Dieter, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael, Kuchenbauer, Florian, Plass, Christoph, Döhner, Hartmut, Stilgenbauer, Stephan, Lichter, Peter, and Mertens, Daniel

Published
2018
Full Text
View/download PDF

224. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor‐risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial

Author

Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Jaramillo, Sonia, Tausch, Eugen, Steinbrecher, Daniela, Hahn, Michael, Böttcher, Sebastian, Ritgen, Matthias, Bunjes, Donald, Zeis, Matthias, Stadler, Michael, Uharek, Lutz, Scheid, Christoph, Hegenbart, Ute, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Döhner, Hartmut, Dreger, Peter, and Stilgenbauer, Stephan

Published
2017
Full Text
View/download PDF

225. TP53 mutation and survival in aggressive B cell lymphoma

Author

Zenz, Thorsten, Kreuz, Markus, Fuge, Maxi, Klapper, Wolfram, Horn, Heike, Staiger, Annette M., Winter, Doris, Helfrich, Hanne, Huellein, Jennifer, Hansmann, Martin‐Leo, Stein, Harald, Feller, Alfred, Möller, Peter, Schmitz, Norbert, Trümper, Lorenz, Loeffler, Markus, Siebert, Reiner, Rosenwald, Andreas, Ott, German, Pfreundschuh, Michael, and Stilgenbauer, Stephan

Published
2017
Full Text
View/download PDF

226. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome

Author

Chigrinova, Ekaterina, Rinaldi, Andrea, Kwee, Ivo, Rossi, Davide, Rancoita, Paola M.V., Strefford, Jonathan C., Oscier, David, Stamatopoulos, Kostas, Papadaki, Theodora, Berger, Francoise, Young, Ken H., Murray, Fiona, Rosenquist, Richard, Greiner, Timothy C., Chan, Wing C., Orlandi, Ester M., Lucioni, Marco, Marasca, Roberto, Inghirami, Giorgio, Ladetto, Marco, Forconi, Francesco, Cogliatti, Sergio, Votavova, Hana, Swerdlow, Steven H., Stilgenbauer, Stephan, Piris, Miguel A., Matolcsy, Andras, Spagnolo, Dominic, Nikitin, Eugene, Zamò, Alberto, Gattei, Valter, Bhagat, Govind, Ott, German, Zucca, Emanuele, Gaidano, Gianluca, and Bertoni, Francesco

Published
2013
Full Text
View/download PDF

227. The genomic and transcriptional landscape of primary central nervous system lymphoma

Author

Radke, Josefine, Ishaque, Naveed, Hostench, Xavier Pastor, Richter, Julia, Rosenstiel, Philip, Rosenwald, Andreas, Schilhabel, Markus, Schreiber, Stefanie, Vater, Inga, Wagener, Rabea, Siebert, Reiner, Bernhart, Stephan H, Binder, Hans, Borgoni, Simone, Doose, Gero, Eils, Roland, Hoffmann, Steve, Hopp, Lydia, Kleinheinz, Kortine, Kretzmer, Helene, Kreuz, Markus, Korbel, Jan, Langenberger, David, Loeffler, Markus, Juraeva, Dilafruz, Rosolowski, Maciej, Stadler, Peter F, Sungalee, Stephanie, Pritsch, Fabienne, Paramasivam, Nagarajan, Balasubramanian, Gnana Prakash, Schlesner, Matthias, Sahay, Shashwat, Weniger, Marc, Pehl, Debora, Koll, Randi, Radbruch, Helena, Osterloh, Anja, Korfel, Agnieszka, Misch, Martin, Onken, Julia, Faust, Katharina, Vajkoczy, Peter, Moskopp, Dag, Wang, Yawen, Jödicke, Andreas, Gu, Zuguang, Trümper, Lorenz, Anagnostopoulos, Ioannis, Lenze, Dido, Küppers, Ralf, Hummel, Michael, Schmitt, Clemens A, Wiestler, Otmar D, Wolf, Stephan, Unterberg, Andreas, Schumann, Elisa, Herold-Mende, Christel, Brors, Benedikt, Consortium, ICGC MMML-Seq, Wiemann, Stefan, Heppner, Frank, Wagner, Susanne, Haake, Andrea, Sieverling, Lina, Richter, Gesine, Lawerenz, Chris, Eils, Jürgen, Kerssemakers, Jules, Jaeger-Schmidt, Christina, Scholz, Ingrid, Bergmann, Anke K, Borst, Christoph, Braulke, Friederike, Uhrig, Sebastian, Burkhardt, Birgit, Claviez, Alexander, Dreyling, Martin, Eberth, Sonja, Einsele, Hermann, Frickhofen, Norbert, Haas, Siegfried, Hansmann, Martin-Leo, Karsch, Dennis, Klepl, Nicole, Hübschmann, Daniel, Kneba, Michael, Lisfeld, Jasmin, Mantovani-Löffler, Luisa, Rohde, Marius, Ott, German, Stadler, Christina, Staib, Peter, Stilgenbauer, Stephan, Zenz, Thorsten, Toprak, Umut H, Kube, Dieter, Klapper, Wolfram, Kostezka, Ulrike, Möller, Peter, Szczepanowski, Monika, Ammerpohl, Ole, Aukema, Sietse M, López, Cristina, Binder, Vera, Borkhardt, Arndt, Hoell, Jessica I, Leich, Ellen, Lichter, Peter, Nagel, Inga, Pischimariov, Jordan, Radlwimmer, Bernhard, Weniger, Marc (Beitragende*r), and Küppers, Ralf (Beitragende*r)

Subjects
Central Nervous System, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Cancer Research, Multidisciplinary, genetics [Central Nervous System Neoplasms], Medizin, General Physics and Astronomy, pathology [Central Nervous System Neoplasms], Genomics, General Chemistry, metabolism [Lymphoma, Large B-Cell, Diffuse], General Biochemistry, Genetics and Molecular Biology, Central Nervous System Neoplasms, hemic and lymphatic diseases, metabolism [Central Nervous System], Humans, ddc:610, Lymphoma, Large B-Cell, Diffuse, ddc:500
Abstract

Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell lymphomas (DLBCLs) confined to the central nervous system (CNS). Molecular drivers of PCNSL have not been fully elucidated. Here, we profile and compare the whole-genome and transcriptome landscape of 51 CNS lymphomas (CNSL) to 39 follicular lymphoma and 36 DLBCL cases outside the CNS. We find recurrent mutations in JAK-STAT, NFkB, and B-cell receptor signaling pathways, including hallmark mutations in MYD88 L265P (67%) and CD79B (63%), and CDKN2A deletions (83%). PCNSLs exhibit significantly more focal deletions of HLA-D (6p21) locus as a potential mechanism of immune evasion. Mutational signatures correlating with DNA replication and mitosis are significantly enriched in PCNSL. TERT gene expression is significantly higher in PCNSL compared to activated B-cell (ABC)-DLBCL. Transcriptome analysis clearly distinguishes PCNSL and systemic DLBCL into distinct molecular subtypes. Epstein-Barr virus (EBV)+ CNSL cases lack recurrent mutational hotspots apart from IG and HLA-DRB loci. We show that PCNSL can be clearly distinguished from DLBCL, having distinct expression profiles, IG expression and translocation patterns, as well as specific combinations of genetic alterations.

Published
2022

228. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Author

Seymour, John F., Byrd, John C., Ghia, Paolo, Kater, Arnon P., Chanan-Khan, Asher, Furman, Richard R., O’Brien, Susan, Brown, Jennifer R., Munir, Talha, Mato, Anthony, Stilgenbauer, Stephan, Bajwa, Naghmana, Miranda, Paulo, Higgins, Kara, John, Ellie, de Borja, Marianne, Jurczak, Wojciech, and Woyach, Jennifer A.

Abstract

•Acalabrutinib has a favorable benefit-risk profile, including lower incidence of cardiovascular-related toxicities, vs ibrutinib.•AE burden score allowed further comparison of the safety of acalabrutinib vs ibrutinib accounting for AE duration, recurrence, and grade.

Published
2023
Full Text
View/download PDF

229. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

Author

Jiang, Qu, Stachelscheid, Johanna, Bloehdorn, Johannes, Pacholewska, Alicja, Aszyk, Christoph, Grotenhuijs, Francien, Müller, Tony, Onder, Ozlem, Wagle, Prerana, Herling, Carmen D., Kleppe, Maria, Wang, Zhefang, Coombes, Kevin R., Robrecht, Sandra, Dalvi, Priya S., Plosnita, Bianca, Mayer, Petra, Abruzzo, Lynne V., Altmüller, Janine, Gathof, Birgit, Persigehl, Thorsten, Fischer, Kirsten, Jebaraj, Billy, Rienhoff, Hugh Y., Ecker, Rupert, Zhao, Yue, Bruns, Christiane J., Stilgenbauer, Stephan, Elenitoba-Johnson, Kojo, Hallek, Michael, Schweiger, Michal R., Odenthal, Margarete, Vasyutina, Elena, and Herling, Marco

Abstract

•KDM1A activation marks high-risk CLL, and genetic KDM1A depletion impedes leukemic growth via cell-intrinsic and milieu-derived programs.•KDM1A loss alters H3 methylation, promoter occupancies, and transcriptomes in CLL alongside apoptotic effects of KDM1A pharmacoinhibition.

Published
2023
Full Text
View/download PDF

230. Mutations driving CLL and their evolution in progression and relapse

Author

Landau, Dan A., Tausch, Eugen, Taylor-Weiner, Amaro N., Stewart, Chip, Reiter, Johannes G., Bahlo, Jasmin, Kluth, Sandra, Bozic, Ivana, Lawrence, Mike, Bottcher, Sebastian, Carter, Scott L., Cibulskis, Kristian, Mertens, Daniel, Sougnez, Carrie L., Rosenberg, Mara, Hess, Julian M., Edelmann, Jennifer, Kless, Sabrina, Kneba, Michael, Ritgen, Matthias, Fink, Anna, Fischer, Kirsten, Gabriel, Stacey, Lander, Eric S., Nowak, Martin A., Dohner, Hartmut, Hallek, Michael, Neuberg, Donna, Getz, Gad, Stilgenbauer, Stephan, and Wu, Catherine J.

Subjects
Gene mutations -- Observations, Metastasis -- Genetic aspects, Chronic lymphocytic leukemia -- Genetic aspects -- Development and progression, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and therapy are central questions in cancer biology. Here we identify 44 recurrently mutated genes and 11 recurrent somatic copy number variations through whole-exome sequencing of 538 chronic lymphocytic leukaemia (CLL) and matched germline DNA samples, 278 of which were collected in a prospective clinical trial. These include previously unrecognized putative cancer drivers (RPS15, IKZF3), and collectively identify RNA processing and export, MYC activity, and MAPK signalling as central pathways involved in CLL. Clonality analysis of this large data set further enabled reconstruction of temporal relationships between driver events. Direct comparison between matched pre-treatment and relapse samples from 59 patients demonstrated highly frequent clonal evolution. Thus, large sequencing data sets of clinically informative samples enable the discovery of novel genes associated with cancer, the network of relationships between the driver events, and their impact on disease relapse and clinical outcome., In recent years, unbiased massively parallel sequencing of whole exornes (WES) in chronic lymphocytic leukaemia (CLL) has yielded fresh insights into the genetic basis of this disease (1-4). Two important [...]

Published
2015
Full Text
View/download PDF

231. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial

Author

von Tresckow, Julia, primary, Cramer, Paula, additional, Robrecht, Sandra, additional, Langerbeins, Petra, additional, Fink, Anna-Maria, additional, Al-Sawaf, Othman, additional, Fürstenau, Moritz, additional, Illmer, Thomas, additional, Klaproth, Holger, additional, Tausch, Eugen, additional, Ritgen, Matthias, additional, Fischer, Kirsten, additional, Wendtner, Clemens-Martin, additional, Kreuzer, Karl-Anton, additional, Stilgenbauer, Stephan, additional, Böttcher, Sebastian, additional, Eichhorst, Barbara F., additional, and Hallek, Michael, additional

Published
2022
Full Text
View/download PDF

232. Abstract 4007: Evolutionary history of transformation from chronic lymphocytic leukemia to Richter’s syndrome

Author

Parry, Erin M., primary, Leshchiner, Ignaty, additional, Guièze, Romain, additional, Johnson, Connor, additional, Tausch, Eugen, additional, Parikh, Sameer, additional, Lemvigh, Camilla, additional, Messer, Conor, additional, Rosebrock, Daniel, additional, Utro, Filippo, additional, Levovitz, Chaya, additional, Rhrissorrakrai, Kahn, additional, Davids, Matthew, additional, Jacobs, Raquel A., additional, Slowik, Kara, additional, Broseus, Julien, additional, Yin, Shanye, additional, Li, Shuqiang, additional, Fell, Geoff, additional, Lin, Ziao, additional, Knisbacher, Binyamin A., additional, Ruthen, Neil, additional, Livitz, Dimitri, additional, Schneider, Christof, additional, Ma, Jialin, additional, Hess, Julian, additional, Rassenti, Laura Z., additional, Kipps, Thomas J., additional, Jain, Nitin, additional, Wierda, William, additional, Cymbalista, Florence, additional, Kay, Neil E., additional, Livak, Kenneth J., additional, Danysh, Brian P., additional, Stewart, Chip, additional, Neuberg, Donna, additional, Brown, Jennifer R., additional, Parida, Laxmi, additional, Stilgenbauer, Stephan, additional, Getz, Gad, additional, and Wu, Catherine J., additional

Published
2022
Full Text
View/download PDF

233. Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

Author

Tausch, Eugen, primary, Ljungström, Viktor, additional, Agathangelidis, Andreas, additional, Zapatka, Marc, additional, Scarfò, Lydia, additional, Jebaraj, Billy Michael Chelliah, additional, Yosifov, Deyan Y., additional, Müller, Annika, additional, Munugalavadla, Veerendra, additional, Degenhardt, Jeremiah D., additional, Ghia, Paolo, additional, Rosenquist, Richard, additional, and Stilgenbauer, Stephan, additional

Published
2022
Full Text
View/download PDF

234. Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Author

Kutsch, Nadine, primary, Pallasch, Christian, additional, Decker, Thomas, additional, Hebart, Holger, additional, Chow, Kai Uwe, additional, Graeven, Ullrich, additional, Kisro, Jens, additional, Kroeber, Alexander, additional, Tausch, Eugen, additional, Fischer, Kirsten, additional, Fink, Anna-Maria, additional, Wendtner, Clemens-Martin, additional, Ritgen, Matthias, additional, Stilgenbauer, Stephan, additional, Zhang, Danjie, additional, Li, Biao, additional, Jürgensmeier, Juliane M., additional, Rajakumaraswamy, Nishanthan, additional, Bhargava, Pankaj, additional, Hallek, Michael, additional, and Eichhorst, Barbara, additional

Published
2022
Full Text
View/download PDF

235. Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax

Author

Fürstenau, Moritz, primary, Weiss, Jonathan, additional, Giza, Adam, additional, Franzen, Fabian, additional, Robrecht, Sandra, additional, Fink, Anna-Maria, additional, Fischer, Kirsten, additional, Schneider, Christof, additional, Tausch, Eugen, additional, Stilgenbauer, Stephan, additional, Ritgen, Matthias, additional, Schilhabel, Anke, additional, Brüggemann, Monika, additional, Eichhorst, Barbara, additional, Hallek, Michael, additional, and Cramer, Paula, additional

Published
2022
Full Text
View/download PDF

236. The EHA Research Roadmap: Malignant Lymphoid Diseases

Author

Dreyling, Martin, primary, André, Marc, additional, Gökbuget, Nicola, additional, Tilly, Hervé, additional, Jerkeman, Mats, additional, Gribben, John, additional, Ferreri, Andrés, additional, Morel, Pierre, additional, Stilgenbauer, Stephan, additional, Fox, Christopher, additional, Maria Ribera, José, additional, Zweegman, Sonja, additional, Aurer, Igor, additional, Bödör, Csaba, additional, Burkhardt, Birgit, additional, Buske, Christian, additional, Dollores Caballero, Maria, additional, Campo, Elias, additional, Chapuy, Bjoern, additional, Davies, Andrew, additional, de Leval, Laurence, additional, Doorduijn, Jeanette, additional, Federico, Massimo, additional, Gaulard, Philippe, additional, Gay, Francesca, additional, Ghia, Paolo, additional, Grønbæk, Kirsten, additional, Goldschmidt, Hartmut, additional, Kersten, Marie-Jose, additional, Kiesewetter, Barbara, additional, Landman-Parker, Judith, additional, Le Gouill, Steven, additional, Lenz, Georg, additional, Leppä, Sirpa, additional, Lopez-Guillermo, Armando, additional, Macintyre, Elizabeth, additional, Mantega, Maria Victoria Mateos, additional, Moreau, Philippe, additional, Moreno, Carol, additional, Nadel, Bertrand, additional, Okosun, Jessica, additional, Owen, Roger, additional, Pospisilova, Sarka, additional, Pott, Christiane, additional, Robak, Tadeusz, additional, Spina, Michelle, additional, Stamatopoulos, Kostas, additional, Stary, Jan, additional, Tarte, Karin, additional, Tedeschi, Allessandra, additional, Thieblemont, Catherine, additional, Trappe, Ralf Ulrich, additional, Trümper, Lorenz H., additional, and Salles, Gilles, additional

Published
2022
Full Text
View/download PDF

237. Modeling the B‐cell receptor signaling on single cell level reveals a stable network circuit topology between non‐malignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors

Author

Wolf, Christine, primary, Maus, Carsten, additional, Persicke, Michael RO, additional, Filarsky, Katharina, additional, Tausch, Eugen, additional, Schneider, Christof, additional, Döhner, Hartmut, additional, Stilgenbauer, Stephan, additional, Lichter, Peter, additional, Höfer, Thomas, additional, and Mertens, Daniel, additional

Published
2022
Full Text
View/download PDF

238. The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia

Author

Rusyn, Lisa, primary, Reinartz, Sebastian, additional, Nikiforov, Anastasia, additional, Mikhael, Nelly, additional, vom Stein, Alexander, additional, Kohlhas, Viktoria, additional, Bloehdorn, Johannes, additional, Stilgenbauer, Stephan, additional, Lohneis, Philipp, additional, Buettner, Reinhard, additional, Robrecht, Sandra, additional, Fischer, Kirsten, additional, Pallasch, Christian, additional, Hallek, Michael, additional, Nguyen, Phuong-Hien, additional, and Seeger-Nukpezah, Tamina, additional

Published
2022
Full Text
View/download PDF

239. Chronic lymphocytic leukemia includes a tumor subset resembling memory B cells that develop early and persist

Author

Budeus, Bettina, primary, Dampmann, Maria, additional, Kibler, Artur, additional, Brauser, Martina, additional, Bronischewski, Kevin, additional, Homp, Ekaterina, additional, Taudien, Sarah, additional, Johansson, Patricia, additional, Bloehdorn, Johannes, additional, Stilgenbauer, Stephan, additional, von Tresckow, Julia, additional, Reinhardt, Hans Christian, additional, Küppers, Ralf, additional, Dürig, Jan, additional, and Seifert, Marc, additional

Published
2022
Full Text
View/download PDF

240. Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma

Author

Lisson, Catharina Silvia, primary, Lisson, Christoph Gerhard, additional, Mezger, Marc Fabian, additional, Wolf, Daniel, additional, Schmidt, Stefan Andreas, additional, Thaiss, Wolfgang M., additional, Tausch, Eugen, additional, Beer, Ambros J., additional, Stilgenbauer, Stephan, additional, Beer, Meinrad, additional, and Goetz, Michael, additional

Published
2022
Full Text
View/download PDF

242. Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszcza – wyniki międzynarodowego, wieloośrodkowego, badania II fazy z ibrutynibem (PCI-32765) – EHA Encore

Author

Jurczak, Wojciech, Rule, Simon, Martin, Peter, Auer, Rebecca, Kahl, Brad S., Giza, Agnieszka, Jachimczak, Bożena, Advani, Ranjana H., Romaguera, Jorge, Williams, Michael, Barrientos, Jacqueline, Chmielowska, Ewa, Radford, John, Stilgenbauer, Stephan, McGreivy, Jesse, Clow, Fong, Beaupre, Darrin M., Kunkel, Lori, Goy, Andre, Blum, Kristie A., Jędrzejczak, Wiktor, and Wang, Michael L.

Published
2013
Full Text
View/download PDF

248. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

Author

Edelmann, Jennifer, Holzmann, Karlheinz, Miller, Florian, Winkler, Dirk, Bühler, Andreas, Zenz, Thorsten, Bullinger, Lars, Kühn, Michael W.M., Gerhardinger, Andreas, Bloehdorn, Johannes, Radtke, Ina, Su, Xiaoping, Ma, Jing, Pounds, Stanley, Hallek, Michael, Lichter, Peter, Korbel, Jan, Busch, Raymonde, Mertens, Daniel, Downing, James R., Stilgenbauer, Stephan, and Döhner, Hartmut

Published
2012
Full Text
View/download PDF

249. Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.

Author

Kutsch, Nadine, Holmes, Emily Eva, Robrecht, Sandra, Schüler, Gudrun, Vehling-Kaiser, Ursula, Decker, Thomas, Müller-Hagen, Sigrun, Heinisch, Karin, Böttcher, Sebastian, Ritgen, Matthias, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Fink, Anna Maria, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, and Wendtner, Clemens-Martin

Subjects
CHRONIC lymphocytic leukemia, PROPOFOL infusion syndrome, LEUCOPENIA, FLUDARABINE
Abstract

Altogether twenty-seven patients with relapsed or refractory CLL were enrolled between December 2014 and December 2017 of which 10 patients received FCG and 17 patients received BG (Supplemental Digital Content (SDC) Figure 1). Before the introduction of targeted oral inhibitors to the treatment of chronic lymphocytic leukemia, chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) as well as bendamustine and rituximab (BR) was considered the standard treatment in fit patients. Patients were mainly treated with targeted substances, in particular ibrutinib [FCG 4 of 6 patients (67%), BG 8 of 8 patients (100%)], which was approved first of all by the EMA. [Extracted from the article]

Published
2023
Full Text
View/download PDF

250. To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?

Author

Urbanek, Karol D., Stilgenbauer, Stephan, and Mertens, Daniel

Subjects
*THERAPEUTIC use of antineoplastic agents, *CHRONIC lymphocytic leukemia, *GENETIC mutation, *CYTOSKELETAL proteins, *WNT proteins, *CELL receptors, *CELLULAR signal transduction, *CELL lines, *CHEMICAL inhibitors
Abstract

Simple Summary: This review aims to present the current state of WNT signaling in chronic lymphocytic leukemia. First, we briefly summarize WNT pathways in physiological conditions and cancer. Then, we focus on WNT pathways in CLL with an emphasis on ROR1. The problem of limited data on canonical WNT signaling in CLL is also highlighted. In conclusion, we suggest that further research should focus on understanding the role of β-catenin signaling in CLL. WNT pathways play an important role in cancer development and progression, but WNT pathways can also inhibit growth in melanoma, prostate, and ovarian cancers. Chronic lymphocytic leukemia (CLL) is known for its overexpression of several WNT ligands and receptors. Canonical WNT signaling is β-catenin-dependent, whereas non-canonical WNT signaling is β-catenin-independent. Research on WNT in CLL focuses mainly on non-canonical signaling due to the high expression of the WNT-5a receptor ROR1. However, it was also shown that mutations in canonical WNT pathway genes can lead to WNT activation in CLL. The focus of this review is β-catenin-independent signaling and β-catenin-dependent signaling within CLL cells and the role of WNT in the leukemic microenvironment. The major role of WNT pathways in CLL pathogenesis also makes WNT a possible therapeutic target, directly or in combination with other drugs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results